Richard Francis Sells 20,025 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) CEO Richard Francis sold 20,025 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $634,191.75. Following the completion of the transaction, the chief executive officer owned 1,170,639 shares in the company, valued at $37,074,137.13. This represents a 1.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Teva Pharmaceutical Industries Stock Up 1.3%

Shares of TEVA stock traded up $0.39 during trading on Monday, hitting $31.44. 11,093,245 shares of the company were exchanged, compared to its average volume of 9,695,220. The business’s 50-day simple moving average is $33.01 and its 200 day simple moving average is $26.32. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $37.35. The firm has a market capitalization of $36.15 billion, a price-to-earnings ratio of 26.20, a P/E/G ratio of 10.39 and a beta of 0.72. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on TEVA. Truist Financial raised their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. The Goldman Sachs Group upped their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Finally, Bank of America raised their target price on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average price target of $37.67.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 24.6% during the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after buying an additional 4,732 shares during the period. Focus Partners Wealth raised its holdings in Teva Pharmaceutical Industries by 4.5% in the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock worth $616,000 after acquiring an additional 1,739 shares during the period. Bank of Montreal Can lifted its position in Teva Pharmaceutical Industries by 15.9% during the 2nd quarter. Bank of Montreal Can now owns 475,937 shares of the company’s stock worth $7,977,000 after acquiring an additional 65,191 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Teva Pharmaceutical Industries by 4.5% during the second quarter. Bank of New York Mellon Corp now owns 1,682,837 shares of the company’s stock valued at $28,204,000 after acquiring an additional 73,141 shares during the period. Finally, Resona Asset Management Co. Ltd. grew its position in shares of Teva Pharmaceutical Industries by 5.3% in the second quarter. Resona Asset Management Co. Ltd. now owns 360,316 shares of the company’s stock valued at $6,039,000 after purchasing an additional 18,093 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.